_
Please Download Flash to complete this viewing experience
You need to upgrade your Flash Player
Clinuvel
Skin & Health
Corporate
SCENESSE®
Alpha-MSH
Melanocortins
Biomimicry
Research
SCENESSE 's Mechanism of Action
Drug Product
Technology updates
Technology Update I
Clinuvel's program
Global Regulatory Progress
Orphan Drug Status
Erythropoietic Protoporphyria (EPP)
Italian Access Scheme - EPP
Skin Cancer in Organ Transplant Patients
Polymorphous Light Eruption (PLE)
Nonsegmental Vitiligo (NSV)
Solar Urticaria (SU)
Photodynamic Therapy (PDT) phototoxicity
Pharmaceutical Development
Preclinical testing
Clinical trials
New Molecular Entity
Green Pharma
Pharmaceutical Regulation
Good Manufacturing Practice (GMP)
Orphan Drug Information
Q & A's
Ask a question
Contact
Corporate Headlines
Clinuvel Strategic Update
Resignation of Non-Executive Director
Appendix 3B & Lapse and Forfeit of Unlisted Conditional Performance Rights
Appendix 4E Preliminary final report
NOMURA Analyst Report
Read More
Recent Headlines
Clinuvel adds to family
Clinuvel seeks thriller repigmentation
Clinuvel - Most interesting logos in Biopharma
SurModics drug delivery tech has day in the sun with Clinuvel
SurModics signs license agreement for UV treatment technology
New drug may bring sufferers light relief
Clinuvel Drug Offers Relief for Rare Light Sensitivity Malady, Study Shows
Webcasts
Vitiligo: a breakthrough therapy
The introduction of SCENESSE in vitiligo treatment.
Recent Blog Updates
Sun protection given by hair: Long versus short
A new program for SCENESSE®: nonsegmental vitiligo
New study into recurrent skin cancer in red heads
Pain measurement in clinical studies: The Likert Scale
Beach umbrellas: Do they really block UV rays?